SparX Biopharmaceutical Corp.
Research-driven, development-stage biopharmaceutical company focused on discovery and development of multispecific antibody therapeutics, nanobody-based ADCs, and related biologics. The company combines machine learning–enabled target discovery, high-throughput antibody engineering, preclinical pharmacology (in vitro and in vivo), and in-house CMC and cGMP manufacturing to advance programs from target identification through IND submission and early clinical development.
Industries
Nr. of Employees
medium (51-250)
SparX Biopharmaceutical Corp.
Products
SPX-303 (LILRB2 × PD-L1 bispecific antibody)
First-in-class bispecific antibody designed to concurrently inhibit LILRB2 and PD-L1 to engage myeloid and T-cell immune checkpoints; underwent IND submission and Phase 1 clinical dosing.
SPX-629 (HER2 dual-payload ADC)
HER2-targeted dual-payload ADC combining topoisomerase I inhibitor and microtubule-disrupting payloads; reported preclinical tumor control and safety window in non-human primate studies.
Nab-style nanobody bi-ADC platform and SPX-802
Nanobody-based bifunctional/biparatopic ADC platform intended to improve tumor penetration, reduce Fc-mediated off-target uptake, and enable alternative delivery routes; SPX-802 cited as a development example.
SPX-303 (LILRB2 × PD-L1 bispecific antibody)
First-in-class bispecific antibody designed to concurrently inhibit LILRB2 and PD-L1 to engage myeloid and T-cell immune checkpoints; underwent IND submission and Phase 1 clinical dosing.
SPX-629 (HER2 dual-payload ADC)
HER2-targeted dual-payload ADC combining topoisomerase I inhibitor and microtubule-disrupting payloads; reported preclinical tumor control and safety window in non-human primate studies.
Nab-style nanobody bi-ADC platform and SPX-802
Nanobody-based bifunctional/biparatopic ADC platform intended to improve tumor penetration, reduce Fc-mediated off-target uptake, and enable alternative delivery routes; SPX-802 cited as a development example.
Services
End-to-end discovery services combining AI-enabled target mining, multiple antibody discovery modalities, and high-throughput optimization to generate multispecific candidates.
Design and development of ADC molecules including payload selection, site-specific conjugation strategies, DAR control and linker optimization.
Clinical and commercial-scale manufacturing support including cell line development, upstream and downstream process development, formulation, and release testing.
End-to-end discovery services combining AI-enabled target mining, multiple antibody discovery modalities, and high-throughput optimization to generate multispecific candidates.
Design and development of ADC molecules including payload selection, site-specific conjugation strategies, DAR control and linker optimization.
Clinical and commercial-scale manufacturing support including cell line development, upstream and downstream process development, formulation, and release testing.
Expertise Areas
- Multispecific and bispecific antibody engineering
- Antibody-drug conjugate design and conjugation
- Nanobody (VHH) discovery and engineering
- Preclinical pharmacology and animal models
Key Technologies
- Machine learning for target discovery
- Phage display
- Hybridoma screening
- Transgenic and humanized mouse models
News & Updates
Company presented Trial-in-Progress poster and participated in a satellite symposium on combining advanced immunotherapy with ADCs; one-year anniversary of first patient dosing.
Research collaboration to advance an ADC program targeting an immune cell antigen with potential cross-tumor application.
Public unveiling and technical presentation of a nanobody-based bifunctional/biparatopic ADC platform and related technologies.
Announcement that the first patient was dosed in the ongoing Phase 1 study of SPX-303 at HonorHealth Research Institute.
Company announced FDA acceptance/clearance to proceed with an IND for SPX-303 enabling initiation of a Phase 1 study.
Letter outlining dual-payload ADC design and bispecific checkpoint strategy as complementary approaches to treat refractory tumors.
Company presented Trial-in-Progress poster and participated in a satellite symposium on combining advanced immunotherapy with ADCs; one-year anniversary of first patient dosing.
Research collaboration to advance an ADC program targeting an immune cell antigen with potential cross-tumor application.
Public unveiling and technical presentation of a nanobody-based bifunctional/biparatopic ADC platform and related technologies.
Announcement that the first patient was dosed in the ongoing Phase 1 study of SPX-303 at HonorHealth Research Institute.
Company announced FDA acceptance/clearance to proceed with an IND for SPX-303 enabling initiation of a Phase 1 study.
Letter outlining dual-payload ADC design and bispecific checkpoint strategy as complementary approaches to treat refractory tumors.